Global Markets Direct: Market Research Reports

Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.

A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.

The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.

With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.

Under the supervision of skillful managers and experts, business analysts produce reports that include:

Product portfolio
Potentially strong market reviews
Competitive analytics
Prospect partners
Mergers and acquisitions project data
Latest trends across a particular industry area
Research and development strategies
The analysis of new customers
A set of remedial measures for projects

They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.

Publications found: 5,853

Sort by:

Limb-Girdle Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Limb-Girdle Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Limb-Girdle Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA,...

May 2022 52 pages

Lipase (EC 3.1.1.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Lipase (EC 3.1.1.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Lipase (EC 3.1.1.) Drugs in Development by Therapy Areas and Indicatio...

May 2022 87 pages

Lipid Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Lipid Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Lipid Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players...

May 2022 213 pages

Lipodystrophy (Lipoatrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Lipodystrophy (Lipoatrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Lipodystrophy (Lipoatrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecu...

May 2022 40 pages

Lipopolysaccharide (Endotoxin) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Lipopolysaccharide (Endotoxin) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Lipopolysaccharide (Endotoxin) Drugs in Development by The...

May 2022 49 pages

Liposarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Liposarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Liposarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides...

May 2022 111 pages

Liver Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Liver Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Liver Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players pr...

May 2022 174 pages

Liver X Receptor (LXR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Liver X Receptor (LXR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Liver X Receptor (LXR) Drugs in Development by Therapy Areas and I...

May 2022 42 pages

Local Anesthetic Effect Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Local Anesthetic Effect Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Local Anesthetic Effect Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 37 pages

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b (CDw32 or Fc Gamma RII-b or CD32 or FCGR2B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Pla...

May 2022 42 pages

Low Density Lipoprotein Receptor Related Protein 6 (LRP6) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Low Density Lipoprotein Receptor Related Protein 6 (LRP6) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Low Density Lipoprotein Recepto...

May 2022 35 pages

Low-Grade Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Low-Grade Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Low-Grade Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Player...

May 2022 55 pages

Lung Adenocarcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Lung Adenocarcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Lung Adenocarcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key...

May 2022 92 pages

Lung Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Lung Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Lung Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provid...

May 2022 80 pages

Lung Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Lung Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Lung Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players...

May 2022 48 pages

Lung Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Lung Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Lung Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides...

May 2022 98 pages

Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key...

May 2022 290 pages

Lupus Nephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Lupus Nephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Lupus Nephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players...

May 2022 86 pages

Lymphoblastic Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Lymphoblastic Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Lymphoblastic Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type an...

May 2022 68 pages

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Lymphocyte Activation...

May 2022 79 pages

Lymphoproliferative Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Lymphoproliferative Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Lymphoproliferative Disorders Drugs in Development by Stages, Target, MoA, RoA, Mo...

May 2022 52 pages

Lymphotoxin Alpha (TNF Beta or Tumor Necrosis Factor Ligand Superfamily Member 1 or LTA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Lymphotoxin Alpha (TNF Beta or Tumor Necrosis Factor Ligand Superfamily Member 1 or LTA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY...

May 2022 41 pages

Lysosomal Storage Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Lysosomal Storage Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Lysosomal Storage Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule...

May 2022 226 pages

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mole...

May 2022 36 pages

Major Depressive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Major Depressive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Major Depressive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule T...

May 2022 153 pages

Major Prion Protein (ASCR or PrP27-30 or PrP33-35C or CD230 or PRNP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Major Prion Protein (ASCR or PrP27-30 or PrP33-35C or CD230 or PRNP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Major Prion Protein...

May 2022 35 pages

Male Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Male Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Male Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 91 pages

Malignant Ascites Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Malignant Ascites Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Malignant Ascites Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Play...

May 2022 35 pages

Malignant Fibrous Histiocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Malignant Fibrous Histiocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Malignant Fibrous Histiocytoma Drugs in Development by Stages, Target, MoA, RoA,...

May 2022 52 pages

Malignant Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Malignant Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Malignant Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Player...

May 2022 94 pages

Malignant Neoplasms Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Malignant Neoplasms Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Malignant Neoplasms Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key...

May 2022 52 pages

Malignant Pleural Mesothelioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Malignant Pleural Mesothelioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Malignant Pleural Mesothelioma Drugs in Development by Stages, Target, MoA, RoA,...

May 2022 125 pages

Mantle Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Mantle Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Mantle Cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Ke...

May 2022 301 pages

Maple Syrup Urine Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Maple Syrup Urine Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Maple Syrup Urine Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule T...

May 2022 39 pages

Marginal Zone B-cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Marginal Zone B-cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Marginal Zone B-cell Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Mo...

May 2022 193 pages

Mast Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Mast Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Mast Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Pl...

May 2022 36 pages

Mast-Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or CD117 or KIT or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Mast-Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or CD117 or KIT...

May 2022 89 pages

Matrix Metalloproteinase (MMP or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Matrix Metalloproteinase (MMP or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Matrix Metalloproteinase (MMP or EC 3.4.24.)...

May 2022 72 pages

Medullary Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Medullary Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Medullary Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Typ...

May 2022 77 pages

Melanoma Associated Antigen 3 (Antigen MZ2D or Cancer-Testis Antigen 1.3 or MAGE3 Antigen or MAGEA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Melanoma Associated Antigen 3 (Antigen MZ2D or Cancer-Testis Antigen 1.3 or MAGE3 Antigen or MAGEA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Play...

May 2022 40 pages

MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY MELAS Syndrome (Mitoc...

May 2022 42 pages

Melatonin Receptor Type 1A (MT1 or MTNR1A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Melatonin Receptor Type 1A (MT1 or MTNR1A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Melatonin Receptor Type 1A (MT1 or MTNR1A) Dru...

May 2022 42 pages

Melatonin Receptor Type 1B (MT2 or MTNR1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Melatonin Receptor Type 1B (MT2 or MTNR1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Melatonin Receptor Type 1B (MT2 or MTNR1B) Dru...

May 2022 41 pages

Membrane Associated Progesterone Receptor Component 1 (Sigma 2 Receptor or PGRMC1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Membrane Associated Progesterone Receptor Component 1 (Sigma 2 Receptor or PGRMC1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Membra...

May 2022 41 pages

Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Membranoproliferative Glomerulonephriti...

May 2022 38 pages

Membranous Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Membranous Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Membranous Glomerulonephritis Drugs in Development by Stages, Target, MoA, RoA, Mo...

May 2022 39 pages

Memory Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Memory Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Memory Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Play...

May 2022 41 pages

Meningioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Meningioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Meningioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides a...

May 2022 55 pages

Menopausal Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Menopausal Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Menopausal Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Ke...

May 2022 51 pages

Mesothelin (CAK1 Antigen or Pre Pro Megakaryocyte Potentiating Factor or MSLN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Mesothelin (CAK1 Antigen or Pre Pro Megakaryocyte Potentiating Factor or MSLN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Mesothelin...

May 2022 37 pages